Fig. 2

CSRP2BP overexpression correlates with a poor prognosis in cervical cancer patients. A and C Western blotting was performed to analyse the expression levels of CSRP2BP in 19 matched pairs of T and ANTs. GAPDH was the internal control. B IHC were used to analyze the specimens derived from human cervical cancer tissues (T) and adjacent noncancerous tissue samples (ANT) (n = 4, Scale bar 20 μm). D Cervical cancer primary cells were isolated from three cervical cancer tissues, and detected the expressions of CD44 (red) and P16 (green) by immunofluorescence staining. Nuclei were counterstained with DAPI (blue). (Scale bar 5 μm). E Western blotting was performed to analyze the expression levels of CSRP2BP in cervical cancer primary cells (T1, T2, T3) and ANTs (ANT1, ANT2, ANT3). F-G Western blotting was used to study the relationship between E6, E7 and CSRP2BP expression. GAPDH was used as loading control. H Kaplan–Meier overall survival curves (left panel), progression-free survival (right panel) and univariate analyses (log-rank) comparing cervical cancer patients with low (n = 101) and high (n = 107) CSRP2BP-expressing tumours. I Kaplan–Meier FIGO stage I overall survival curves (left panel), FIGO stage II overall survival curves (right panel) and univariate analyses (log-rank) comparing cervical cancer patients with low and high CSRP2BP-expression tumours. (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001)